Not independent
Tenure on this board
1.4 yrs
5 nominees · 2 ballot items.
Proposal 1: Approve Amendment No. 2 to the Investment Management Trust Agreement to change the monthly extension contribution to the lesser of $50,000 and $0.033 per then-outstanding public share; Proposal 2: Authorize the chairman to adjourn the Special Meeting to allow additional solicitation if there are insufficient votes to approve the Trust Amendment.
Amend the Trust Agreement to provide that for each one-month extension to consummate an initial business combination the Company will deposit into the Trust Account the lesser of (i) US$50,000 and (ii) US$0.033 per then-outstanding public share, replacing the prior $125,000-per-month sponsor contribution framework.
This proposal seeks shareholder approval to amend the Investment Management Trust Agreement so that for each one-month extension of the Company’s deadline to complete an initial business combination the Company will deposit into the Trust Account the lesser of US$50,000 and US$0.033 per then-outstanding public share. Management is pursuing the amendment because the Sponsor has indicated it will not fund monthly contributions in excess of US$50,000, and the existing Trust Agreement requires larger monthly contributions (previously disclosed as US$125,000) to effectuate extensions. Approval would not change the termination date but would materially reduce the incremental amounts added to the Trust Account for each extension, lowering the per-share redemption increment compared to the prior $125,000 monthly contribution and potentially reducing the economic protection for public shareholders if many shares remain outstanding. The Sponsor or its designees are expected to deposit the Monthly Contribution when an extension is elected, and any such contribution would be structured as a non-interest-bearing, unsecured loan repayable only upon consummation of a business combination, meaning the Sponsor bears downside if liquidation occurs. The proposal requires a special 65% approval threshold of issued and outstanding ordinary shares (including Founder Shares), which increases reliance on sponsor and insider-aligned voting and makes broker non-votes effectively adverse. If not approved, the Company may be unable to exercise its existing extension rights (given the Sponsor’s $50,000 cap) and could be forced to liquidate if a business combination is not consummated by the Termination Date. The Board recommends the amendment to preserve flexibility to complete the pending business combination with DRC Medicine Ltd. and to avoid immediate liquidation risk, but shareholders should weigh that benefit against dilution of prospective per-share trust increases and the potential for conflicts of interest given the Sponsor’s incentives.
Authorize the chairman of the Special Meeting to adjourn the meeting to a later date or dates, if necessary, to permit further solicitation and voting of proxies if there are insufficient votes to approve the Trust Amendment Proposal.
The Adjournment Proposal requests a simple majority vote to empower the chairman to adjourn the Special Meeting to one or more later dates solely to permit additional solicitation of proxies if there are insufficient votes to approve the Trust Amendment at the time of the meeting. Management proposes this contingency to increase the likelihood of obtaining the high 65% approval threshold required for the Trust Amendment without otherwise altering substantive shareholder rights. The proposal is procedural and would allow the Company to resume solicitations and attempt to garner additional support from holders who have not voted or who may be persuaded to retain shares rather than redeem. While routine (brokers may exercise discretionary authority on this matter), adjournment could prolong uncertainty for public shareholders and may enable strategic purchases or arrangements by the Sponsor or affiliates (subject to representations that such purchased shares will not be voted in favor of the Trust Amendment if tender rules apply). If the Adjournment Proposal is not approved, the chairman would not adjourn for further solicitation and the Trust Amendment would be decided on the votes then available, potentially resulting in a failed 65% vote and subsequent liquidation risk. The Board recommends voting for the adjournment as a practical measure to ensure shareholders have sufficient opportunity to consider and vote on the material Trust Amendment proposal.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | RIVERNORTH CAPITAL MANAGEMENT, LLC | 7.98% | 400,000 | $4M |
| 2 | Westchester Capital Management, LLC | 6.88% | 344,981 | $4M |
| 3 | WOLVERINE ASSET MANAGEMENT LLC | 6.00% | 300,790 | $3M |
| 4 | BERKLEY W R CORP | 5.94% | 297,589 | $3M |
| 5 | Hudson Bay Capital Management LP | 4.99% | 250,000 | $3M |
| 6 | Karpus Management, Inc.Activist | 4.35% | 218,287 | $2M |
| 7 | AQR Arbitrage LLC | 3.70% | 185,283 | $2M |
| 8 | D. E. Shaw Co., Inc.Activist | 2.99% | 150,000 | $2M |
| 9 | GABELLI Co INVESTMENT ADVISERS, INC. | 2.78% | 139,200 | $1M |
| 10 | Shaolin Capital Management LLC | 2.39% | 120,000 | $1M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.